Kura Oncology (KURA) EBT Margin (2025 - 2026)
Kura Oncology (KURA) reported EBT Margin of 401.45% for Q1 2026, up 401.0% year-over-year from 80.13% in Q1 2025, and down 135.25% quarter-over-quarter from 1138.91% in Q4 2025.
Kura Oncology (KURA) EBT Margin (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has 2 years of EBT Margin data on file, last reported at 401.45% in Q1 2026.
- EBT Margin for Q1 2026 came in at 401.45%, up 401.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 22.5% (changed N/A YoY), and the FY2024 annual result was 319.15%, changed N/A from the prior year.
- EBT Margin retreated to 401.45% in Q1 2026 per KURA's latest filing, from 1138.91% in the prior quarter.
- Over five years, EBT Margin peaked at 1138.91% in Q4 2025 and troughed at 432.51% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | -401.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -401.45% |
| Dec 31, 2025 | 1,138.91% |
| Sep 30, 2025 | -357.19% |
| Jun 30, 2025 | -432.51% |
| Mar 31, 2025 | -405.46% |